glutamate metabotropic receptor 6
Dernière mise à jour 11 avr. 2023
Respecte les directives éditoriales
- TéléchargerTélécharger
- Partager
- Language
- Discussion
- Ask Patient
- Version audio
- Ajouter aux sources préférées sur Google
La GRM6 gene provides instructions for making a protein called metabotropic glutamate receptor 6 (mGluR6). This protein is a glutamate receptor, which is a type of protein that attaches (binds) to the signaling molecule glutamate on the surface of cells. The mGluR6 protein is found within the membrane that surrounds cells called bipolar cells, which are part of the light-sensitive tissue at the back of the eye (retina). Bipolar cells receive visual signals from cells called rods that are used to see in low light. Rod cells release glutamate, which then binds to mGluR6 on bipolar cells. This binding ultimately triggers bipolar cells to transmit the visual signals to other retinal cells and eventually to the brain.
Sélections vidéo pour GènesBibliothèque vidéo
Normal function
La GRM6 gene provides instructions for making a protein called metabotropic glutamate receptor 6 (mGluR6). This protein is a glutamate receptor, which is a type of protein that attaches (binds) to the signaling molecule glutamate on the surface of cells. The mGluR6 protein is found within the membrane that surrounds cells called bipolar cells, which are part of the light-sensitive tissue at the back of the eye (retina). Bipolar cells receive visual signals from cells called rods that are used to see in low light. Rod cells release glutamate, which then binds to mGluR6 on bipolar cells. This binding ultimately triggers bipolar cells to transmit the visual signals to other retinal cells and eventually to the brain.
Conditions referring to this gene or chromosome
Other names
glutamate receptor, metabotropic 6
GPRC1F
GRM6_HUMAN
metabotropic glutamate receptor 6
mGlu6
MGLUR6
Related patient information and medicines

Patient information leaflet
Mastocytose et troubles des mastocytes
Emotional triggers - for example, stress. Some foods - for example, cheese, spices, shellfish, food preservatives, flavourings and colourings, monosodium glutamate. Toxic substances in the environment - for example, perfumes, pesticides. Dr Sarah Jarvis , 28th September 2021 Midostaurin for treating advanced systemic mastocytosis The National.

Patient information leaflet
Maladie du motoneurone
Riluzole Riluzole is a medicine which has been shown in clinical trials to have a beneficial effect on the survival of people with ALS-MND. It can slow down the disease progression by a few months. Riluzole works by its effect on glutamate - a chemical which relays signals between a nerve and another cell in the central nervous system. Glutamate.

Patient information leaflet
Diabète et maladie
Further information on managing diabetes pendant a period of illness is available on the Diabetes UK site web (see Further Reading below for the link). There is... On Agonistes des récepteurs GLP-1 ( dulaglutide Dulaglutide injections for type 2 diabetes , exenatide Exenatide for diabetes , liraglutide Liraglutide for diabetes , lixisenatide Lixisenatide.

Patient information leaflet
Maladie rénale diabétique
With more severe kidney disease, symptoms that may develop include: Difficulty thinking clearly. A poor appetite. Weight loss. Dry, itchy skin. Muscle cramps. Fluid retention which causes swollen feet and ankles. Puffiness around the eyes. Needing to pass urine more often than usual. Being pale due to anaemia. Feeling sick (nausea). As the kidney.

Patient information leaflet
Myasthénie grave
Myasthenia gravis (MG) is a condition where muscles become easily fatigué et faible. It is due to a problem with how the nerves stimulate the muscles to tighten (contract). The muscles around the eyes are commonly affected first. What causes myasthenia gravis. Myasthénie grave est an autoimmune disease. This means that the immune system The immune.

Patient information leaflet
Puis-je prendre Chaga et Cordyceps ensemble ?
Taking chaga and cordyceps together may increase the risk of bruising or bleeding. Using other medicines Taking multiple medicines. Our Vérificateur d'Interactions Médicamenteuses helps you check whether your prescriptions, over-the-counter medicines, et suppléments are safe to take together. Disclaimer This information is for general educational purposes only.
Lectures complémentaires et références
- glutamate metabotropic receptor 6; MedlinePlus, National Library of Medicine.
- Beqollari D, Betzenhauser MJ, Kammermeier PJ. Altered G-protein coupling in an mGluR6 point mutant associated with congenital stationary night blindness. Mol Pharmacol. 2009 Nov;76(5):992-7. doi: 10.1124/mol.109.058628. Epub 2009 Aug 7.
- Dryja TP, McGee TL, Berson EL, Fishman GA, Sandberg MA, Alexander KR, Derlacki DJ, Rajagopalan AS. Night blindness and abnormal cone electroretinogram ON responses in patients with mutations in the GRM6 gene encoding mGluR6. Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4884-9. doi: 10.1073/pnas.0501233102. Epub 2005 Mar 21.
- Sergouniotis PI, Robson AG, Li Z, Devery S, Holder GE, Moore AT, Webster AR. A phenotypic study of congenital stationary night blindness (CSNB) associated with mutations in the GRM6 gene. Acta Ophthalmol. 2012 May;90(3):e192-7. doi: 10.1111/j.1755-3768.2011.02267.x. Epub 2011 Oct 19.
- Wang Q, Gao Y, Li S, Guo X, Zhang Q. Mutation screening of TRPM1, GRM6, NYX and CACNA1F genes in patients with congenital stationary night blindness. Int J Mol Med. 2012 Sep;30(3):521-6. doi: 10.3892/ijmm.2012.1039. Epub 2012 Jun 20.
- Zeitz C, Forster U, Neidhardt J, Feil S, Kalin S, Leifert D, Flor PJ, Berger W. Night blindness-associated mutations in the ligand-binding, cysteine-rich, and intracellular domains of the metabotropic glutamate receptor 6 abolish protein trafficking. Hum Mutat. 2007 Aug;28(8):771-80. doi: 10.1002/humu.20499.
- Zeitz C, van Genderen M, Neidhardt J, Luhmann UF, Hoeben F, Forster U, Wycisk K, Matyas G, Hoyng CB, Riemslag F, Meire F, Cremers FP, Berger W. Mutations in GRM6 cause autosomal recessive congenital stationary night blindness with a distinctive scotopic 15-Hz flicker electroretinogram. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4328-35. doi: 10.1167/iovs.05-0526.
Partagez vos pensées ou expériences avec les autres dans notre communautés de patients.
Inscrivez-vous à la newsletter Patient
Votre dose hebdomadaire de conseils de santé clairs et fiables - rédigés pour vous aider à vous sentir informé, confiant et maître de la situation.
En vous abonnant, vous acceptez notre Politique de confidentialité. Vous pouvez vous désabonner à tout moment. Nous ne vendons jamais vos données.

